Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor ...

What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 3.8% in the afternoon session after ...

Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

In the past week, Wolfe Research upgraded Vertex Pharmaceuticals from “Peer Perform” to “Outperform,” citing growing ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...

Three different three-drug regimens all provided dramatic results against cystic fibrosis, a fatal disease of the lungs and digestive system that afflicts 75,000 people worldwide. The results are a ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Just last week, I wrote why you'd be smart to buy Vertex Pharmaceuticals (VRTX-0.63%) stock. At that time, Vertex was up around 70% for the year. My argument then was that the stock was still ...

Vertex Flooring introduces distinctive marquetry flooring crafted with expert precision, offering custom wood designs ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...